For the quarter ending 2025-09-30, ELDN made $19,553,000 in revenue. -$17,459,000 in net income. Net profit margin of -89.29%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Provision for income taxes | - | - | - | 107,750 |
| Research and development | 14,969,000 | 20,276,000 | 13,531,000 | 12,991,000 |
| General and administrative | 4,101,000 | 4,457,000 | 4,433,000 | 4,653,250 |
| Total operating expenses | 19,070,000 | 24,733,000 | 17,964,000 | 17,644,250 |
| Loss from operations | -19,070,000 | -24,733,000 | -17,964,000 | - |
| Other income, net | 1,047,000 | 1,224,000 | 1,409,000 | 981,000 |
| Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds | - | - | -10,060,000 | -7,725,000 |
| Loss before income taxes | - | - | - | -8,938,250 |
| Change in fair value of warrant liabilities | -564,000 | -12,293,000 | - | - |
| Net income (loss) | -17,459,000 | -11,216,000 | -6,495,000 | -9,046,000 |
| Earnings per share, basic, total | -0.21 | -0.13 | -0.08 | - |
| Earnings per share, diluted, total | -0.21 | -0.13 | -0.08 | - |
| Weighted average number of shares outstanding, basic, total | 77,156,068 | 77,156,068 | 77,126,763 | - |
| Weighted average number of shares outstanding, diluted, total | 77,156,068 | 77,156,068 | 77,126,763 | - |
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)